|
1
|
Cao R, Wang Y and Huang N: Discovery of
2-acylaminothiophene-3-carboxamides as multitarget inhibitors for
BCR-ABL kinase and microtubules. J Chem Inf Model. 55:2435–2442.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mathisen MS, Kantarjian HM, Cortes J and
Jabbour E: Mutant BCR-ABL clones in chronic myeloid leukemia.
Haematologica. 96:347–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yandim MK, Ceylan C, Elmas E and Baran Y:
A molecular and biophysical comparison of macromolecular changes in
imatinib-sensitive and imatinib-resistant K562 cells exposed to
ponatinib. Tumour Biol. 37:2365–2378. 2016. View Article : Google Scholar
|
|
4
|
O’Hare T, Shakespeare WC, Zhu X, Eide CA,
Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al:
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia,
potently inhibits the T315I mutant and overcomes mutation-based
resistance. Cancer Cell. 16:401–412. 2009. View Article : Google Scholar
|
|
5
|
Sweet K and Pinilla-Ibarz J: Early switch
in tyrosine kinase inhibitor therapy for patients with chronic
myeloid leukemia: An emerging clinical question. Crit Rev Oncol
Hematol. 103:99–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hochhaus A, Ernst T, Eigendorff E and La
Rosée P: Causes of resistance and treatment choices of second- and
third-line treatment in chronic myelogenous leukemia patients. Ann
Hematol. 94(Suppl 2): S133–S140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
La Rosée P, Corbin AS, Stoffregen EP,
Deininger MW and Druker BJ: Activity of the Bcr-Abl kinase
inhibitor PD180970 against clinically relevant Bcr-Abl isoforms
that cause resistance to imatinib mesylate (Gleevec, STI571).
Cancer Res. 62:7149–7153. 2002.PubMed/NCBI
|
|
8
|
Corrêa S, Binato R, Du Rocher B,
Castelo-Branco MT, Pizzatti L and Abdelhay E: Wnt/β-catenin pathway
regulates ABCB1 transcription in chronic myeloid leukemia. BMC
Cancer. 12:3032012. View Article : Google Scholar
|
|
9
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: From genomics to mechanism.
Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kalle AM, Sachchidanand S and Pallu R:
Bcr-Abl-independent mechanism of resistance to imatinib in K562
cells: Induction of cyclooxygenase-2 (COX-2) by histone
deacetylases (HDACs). Leuk Res. 34:1132–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoegg S and Meyer A: Hox clusters as
models for vertebrate genome evolution. Trends Genet. 21:421–424.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cillo C, Cantile M, Faiella A and
Boncinelli E: Homeobox genes in normal and malignant cells. J Cell
Physiol. 188:161–169. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li N, Jia X, Wang J, Li Y and Xie S:
Knockdown of homeobox A5 by small hairpin RNA inhibits
proliferation and enhances cytarabine chemosensitivity of acute
myeloid leukemia cells. Mol Med Rep. 12:6861–6866. 2015.PubMed/NCBI
|
|
15
|
Yi YJ, Jia XH, Wang JY, Li YJ, Wang H and
Xie SY: Knockdown of HOXA10 reverses the multidrug resistance of
human chronic mylogenous leukemia K562/ADM cells by downregulating
P-gp and MRP-1. Int J Mol Med. 37:1405–1411. 2016.PubMed/NCBI
|
|
16
|
Kavalerchik E, Goff D and Jamieson CH:
Chronic myeloid leukemia stem cells. J Clin Oncol. 26:2911–2915.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thorén LA, Liuba K, Bryder D, Nygren JM,
Jensen CT, Qian H, Antonchuk J and Jacobsen SE: Kit regulates
maintenance of quiescent hematopoietic stem cells. J Immunol.
180:2045–2053. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang XB, Beard BC, Trobridge GD, Wood BL,
Sale GE, Sud R, Humphries RK and Kiem HP: High incidence of
leukemia in large animals after stem cell gene therapy with a
HOXB4-expressing retroviral vector. J Clin Invest. 118:1502–1510.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bodey B, Bodey B Jr, Siegel SE and Kaiser
HE: Immunocytochemical detection of the homeobox B3, B4, and C6
gene products in breast carcinomas. Anticancer Res. 20(5A):
3281–3286. 2000.PubMed/NCBI
|
|
20
|
Bodey B, Bodey B Jr, Gröger AM, Siegel SE
and Kaiser HE: Immunocytochemical detection of homeobox B3, B4, and
C6 gene product expression in lung carcinomas. Anticancer Res.
20:2711–2716. 2000.PubMed/NCBI
|
|
21
|
Hwang SH, Kim KU, Kim JE, Kim HH, Lee MK,
Lee CH, Lee SY, Oh T and An S: Detection of HOXA9 gene methylation
in tumor tissues and induced sputum samples from primary lung
cancer patients. Clin Chem Lab Med. 49:699–704. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rodríguez-Rodero S, Fernández AF,
Fernández-Morera JL, Castro-Santos P, Bayon GF, Ferrero C,
Urdinguio RG, Gonzalez-Marquez R, Suarez C, Fernández-Vega I, et
al: DNA methylation signatures identify biologically distinct
thyroid cancer subtypes. J Clin Endocrinol Metab. 98:2811–2821.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jamieson CH, Ailles LE, Dylla SJ,
Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating
A, et al: Granulocyte-macrophage progenitors as candidate leukemic
stem cells in blast-crisis CML. N Engl J Med. 351:657–667. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morgan R, Simpson G, Gray S, Gillett C,
Tabi Z, Spicer J, Harrington KJ and Pandha HS: HOX transcription
factors are potential targets and markers in malignant
mesothelioma. BMC Cancer. 16:852016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kelly Z, Moller-Levet C, McGrath S,
Butler-Manuel S, Kavitha Madhuri T, Kierzek AM, Pandha H, Morgan R
and Michael A: The prognostic significance of specific HOX gene
expression patterns in ovarian cancer. Int J Cancer. 139:1608–1617.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gordon-Keylock SA, Jackson M, Huang C,
Samuel K, Axton RA, Oostendorp RA, Taylor H, Wilson J and Forrester
LM: Induction of hematopoietic differentiation of mouse embryonic
stem cells by an AGM-derived stromal cell line is not further
enhanced by overexpression of HOXB4. Stem Cells Dev. 19:1687–1698.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lehne G, Grasmo-Wendler UH, Berner JM,
Meza-Zepeda LA, Adamsen BL, Flack A, Reiner A, Clausen OP, Hovig E
and Myklebost O: Upregulation of stem cell genes in multidrug
resistant K562 leukemia cells. Leuk Res. 33:1379–1385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sheng Z, Ma L, Sun JE, Zhu LJ and Green
MR: BCR-ABL suppresses autophagy through ATF5-mediated regulation
of mTOR transcription. Blood. 118:2840–2848. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie X, Tang B, Zhou J, Gao Q and Zhang P:
Inhibition of the PI3K/Akt pathway increases the chemosensitivity
of gastric cancer to vincristine. Oncol Rep. 30:773–782.
2013.PubMed/NCBI
|
|
30
|
Cheng L, Luo S, Jin C, Ma H, Zhou H and
Jia L: FUT family mediates the multidrug resistance of human
hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell
Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mao Z, Zhou J, Luan J, Sheng W, Shen X and
Dong X: Tamoxifen reduces P-gp-mediated multidrug resistance via
inhibiting the PI3K/Akt signaling pathway in ER-negative human
gastric cancer cells. Biomed Pharmacother. 68:179–183. 2014.
View Article : Google Scholar
|
|
32
|
Tazzari PL, Cappellini A, Ricci F,
Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L,
McCubrey JA, et al: Multidrug resistance-associated protein 1
expression is under the control of the phosphoinositide 3
kinase/Akt signal transduction network in human acute myelogenous
leukemia blasts. Leukemia. 21:427–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang H, Jia XH, Chen JR, Wang JY and Li
YJ: Osthole shows the potential to overcome P-glycoprotein-mediated
multidrug resistance in human myelogenous leukemia K562/ADM cells
by inhibiting the PI3K/Akt signaling pathway. Oncol Rep.
35:3659–3668. 2016.PubMed/NCBI
|
|
34
|
Chen JR, Jia XH, Wang H, Yi YJ, Wang JY
and Li YJ: Timosaponin A-III reverses multi-drug resistance in
human chronic myelogenous leukemia K562/ADM cells via
downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt
signaling pathway. Int J Oncol. 48:2063–2070. 2016.PubMed/NCBI
|
|
35
|
Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY,
Li WJ, Chen XP, Zhao XL, Chen FP and Zeng H: Inactivation of PTEN
increases ABCG2 expression and the side population through the
PI3K/Akt pathway in adult acute leukemia. Cancer Lett. 336:96–105.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H
and Jia L: Reversal effect of ST6GAL 1 on multidrug resistance in
human leukemia by regulating the PI3K/Akt pathway and the
expression of P-gp and MRP1. PLoS One. 9:e851132014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang X, Dong W, Zhou H, Li H, Wang N,
Miao X and Jia L: α-2,8-sialyltransferase is involved in the
development of multidrug resistance via PI3K/Akt pathway in human
chronic myeloid leukemia. IUBMB Life. 67:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng Z, Yang N, Liang W, Yan X, Li L and
Pan L: Effect of phosphatase and tensin homology deleted on
chromosome 10 (PTEN) gene transfection on reversal of multidrug
resistance in K562/ADM cells. Leuk Lymphoma. 53:1383–1389. 2012.
View Article : Google Scholar
|
|
39
|
Morishita N, Tsukahara H, Chayama K,
Ishida T, Washio K, Miyamura T, Yamashita N, Oda M and Morishima T:
Activation of Akt is associated with poor prognosis and
chemotherapeutic resistance in pediatric B-precursor acute
lymphoblastic leukemia. Pediatr Blood Cancer. 59:83–89. 2012.
View Article : Google Scholar
|
|
40
|
Jung KA, Choi BH and Kwak MK: The
c-MET/PI3K signaling is associated with cancer resistance to
doxorubicin and photodynamic therapy by elevating BCRP/ABCG2
expression. Mol Pharmacol. 87:465–476. 2015. View Article : Google Scholar
|
